Skip to main content

Table 1 Baseline characteristics of the experimental dataset

From: Utilizing dynamic treatment information for MACE prediction of acute coronary syndrome

Characteristics No. of participants (n = 2930)
Demographics
 Age, (mean ± sdv.) [min-max] 62.27 ± 12.11 [28–91]
 Gender, Male/Female 2079/851
Physical examination, (mean ± sdv.) [min-max]
 Systolic BP, mm Hg 132.10 ± 17.64 [11–240]
 Diastolic BP, mm Hg 77.59 ± 10.17 [35–120]
 Height, cm 167.01 ± 8.15 [56–188]
 Weight, kg 71.81 ± 12.42 [32–200]
 Ejection Fraction, (mean ± sdv.) [min-max] 59.51 ± 7.82 [17–78]
Comorbid conditions (%)
 Diabetes 803 (27.4%)
 Hypertension 1981 (67.6%)
 Heart Failure 165 (5.6%)
 arteriosclerosis 2267 (77.4%)
 History of current or previous smoking 1113 (38.0%)
Laboratory data, (mean ± sdv.) [min-max]
 Creatinine, umol/L 78.72 ± 38.18 [29.5–739.4]
 Creatinine kinase, umol/L 86.11 ± 112.02 [6.2–4651.1]
 Alanine aminotransferase, umol/L 26.02 ± 27.66 [1.7–593]
 Aspartate aminotransferase, umol/L 21.70 ± 19.53 [5.8–589.4]
 Troponin T, ng/ml 0.029 ± 0.084 [0.002–0.886]
 Glucose, umol/L 6.16 ± 2.26 [2.69–28.62]
Disease/Treatment history (%)
 Post-PCI (patient who has taken PCI surgery in the past and was admitted into the hospital at this time) 816 (27.8%)
 Post-CABG (patient who has taken CABG surgery in the past and was admitted into the hospital at this time) 46 (1.6%)
Length of Stay, (mean ± sdv.) [min-max] 9.12 ± 7.05 [1–54]
MACE (%) 752 (22.4%)